SCHEMBL612939

SCHEMBL612939

CN(C)c1ccc2cc(S(N)(=O)=O)ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
CA2 P00918 12/20 0.54
CA9 Q16790 7/20 0.54
CA12 O43570 5/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
POLB P06746 1/20 0.54
CA1 P00915 9/20 0.53
NSD2 O96028 1/20 0.51
CA7 P43166 1/20 0.47
PTGS2 P35354 2/20 0.46
PTGS1 P23219 1/20 0.46
CA4 P22748 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TERT O14746 1/20 0.42
APP P05067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14356134 0.83 NSD2 (0.49) CA2CA9CA12NPC1RAB9A
SCHEMBL9839080 0.82 LMNA (0.82) LMNACA2CA9CA12RAB9A
SCHEMBL2763826 0.81 NSD2 (0.69) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL28493030 0.81 NSD2 (0.47) LMNACA2CA9CA12NPC1
SCHEMBL2015756 0.81 NSD2 (0.47) LMNACA2CA9CA12NPC1
SCHEMBL29289316 0.80 NSD2 (0.67) LMNANPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL27908422 0.80 NSD2 (0.67) LMNANPC1RAB9AMEN1KMT2A
SCHEMBL330045 0.80 CA2 (0.78) CA2CA9CA12NPC1RAB9A
SCHEMBL7893669 0.77 NSD2 (0.58) NPC1RAB9ANSD2HTTNPSR1
SCHEMBL9096882 0.77 CA2 (0.61) CA2CA9CA12NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10967096-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-04-06 US disclosed
US-10960104-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-03-30 US disclosed
US-10881759-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2021-01-05 US disclosed
US-20190192727-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2019-06-27 US disclosed
US-20190192728-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2019-06-27 US disclosed
US-20160331862-A1 TISSUE SEALANT COMPOSITIONS, VASCULAR CLOSURE DEVICES, AND USES THEREOF MALLINCKRODT INC. 2016-11-17 US disclosed
US-9433700-B2 Tissue sealant compositions, vascular closure devices, and uses thereof MEDIBEACON INC. (US) 2016-09-06 US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-7297495-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2007-11-20 US disclosed
US-7297495-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2007-11-20 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES INC. (US) 2007-07-19 US disclosed
US-6951930-B2 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2005-10-04 US disclosed
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids EPOCH BIOSCIENCES, INC. (US) 2003-06-19 US disclosed
US-6472153-B1 COVALENTLY BOUND OLIGONUCLEOTIDE/MINOR GROOVE BINDER/LATENT FLUOROPHORE COMBINATION EPOCH BIOSCIENCES, INC. 2002-10-29 US disclosed
EP-1224332-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS Epoch Biosciences, Inc. (US) 2002-07-24 EP disclosed
WO-2001031063-A1 HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS EPOCH BIOSCIENCES, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166723-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 LMNA 347/4885CA2 692/4885CA9 567/4885
US-20030113765-A1 Hybridization-triggered fluorescent detection of nucleic acids DDX21, RNGTT, NOP2 LMNA 347/4885CA2 692/4885CA9 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.